These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27249750)

  • 1. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
    Avet-Loiseau H
    Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
    Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
    Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
    Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
    Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
    Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
    Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
    Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
    Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
    J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
    Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
    Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
    Cedena MT; Martin-Clavero E; Wong S; Shah N; Bahri N; Alonso R; Barcenas C; Valeri A; Salazar Tabares J; Sanchez-Pina J; Cuellar C; Martin T; Wolf J; Lahuerta JJ; Martinez-Lopez J
    PLoS One; 2020; 15(8):e0237155. PubMed ID: 32866200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
    Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
    Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
    Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
    Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
    Munshi NC; Avet-Loiseau H; Rawstron AC; Owen RG; Child JA; Thakurta A; Sherrington P; Samur MK; Georgieva A; Anderson KC; Gregory WM
    JAMA Oncol; 2017 Jan; 3(1):28-35. PubMed ID: 27632282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
    Mailankody S; Korde N; Lesokhin AM; Lendvai N; Hassoun H; Stetler-Stevenson M; Landgren O
    Nat Rev Clin Oncol; 2015 May; 12(5):286-95. PubMed ID: 25622976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
    Goicoechea I; Puig N; Cedena MT; Burgos L; Cordón L; Vidriales MB; Flores-Montero J; Gutierrez NC; Calasanz MJ; Ramos MM; Lara-Astiaso D; Vilas-Zornoza A; Alignani D; Rodriguez I; Sarvide S; Alameda D; Garcés JJ; Rodriguez S; Fresquet V; Celay J; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Rios R; Martin-Sanchez J; Martinez-Martinez R; Sarra J; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Martinez-Climent JA; Orfao A; Rosiñol L; Mateos MV; Lahuerta JJ; Blade J; San Miguel J; Paiva B
    Blood; 2021 Jan; 137(1):49-60. PubMed ID: 32693406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
    Takamatsu H
    Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.